Acalabrutinib for mantle cell lymphoma

Blood. 2019 Jun 13;133(24):2570-2574. doi: 10.1182/blood.2019852368. Epub 2019 Apr 9.

Abstract

Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides / therapeutic use*
  • Humans
  • Lymphoma, Mantle-Cell / drug therapy*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazines / therapeutic use*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Protein Kinase Inhibitors
  • Pyrazines
  • acalabrutinib